High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Inclusion Criteria: * Documented informed consent of the participant * Age: ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) ≤ 2 * Postmenopausal by last menses \> 12 months or medically induced menopause in premenopausal women for AI therapy use * At least 5 years since other malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I or II cancer from which the patient is currently in complete remission * Ability to read and understand English, Spanish, or translations by interpreters for questionnaires * Histologically confirmed primary invasive adenocarcinoma of the breast or ductal carcinoma in situ of the breast * Stage 0, I, II, or IIIA disease * No metastatic disease * Must have undergone definitive breast cancer surgery and recovered * Must have completed adjuvant chemotherapy as applicable, including systemic chemotherapy, anti-HER2 therapy, and/or radiation therapy * Estrogen-receptor positive (ER+) and/or progesterone-receptor positive (PR+) * Currently taking a third-generation aromatase inhibitor (AI) (e.g., anastrozole \[Arimidex (registered trademark)\], letrozole \[Femara (registered trademark)\], or exemestane \[Aromasin (registered trademark)\]) for ≥ 90 days prior to registration with plans to continue for ≥ 180 days after registration * Must have a worst pain/stiffness of ≥ 4 on the Brief Pain Inventory (BPI) (item #2) that has started or increased with AI therapy Exclus…